199 related articles for article (PubMed ID: 20945323)
1. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Sekeres MA; Kantarjian H; Fenaux P; Becker P; Boruchov A; Guerci-Bresler A; Hu K; Franklin J; Wang YM; Berger D
Cancer; 2011 Mar; 117(5):992-1000. PubMed ID: 20945323
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
Wang ES; Lyons RM; Larson RA; Gandhi S; Liu D; Matei C; Scott B; Hu K; Yang AS
J Hematol Oncol; 2012 Nov; 5():71. PubMed ID: 23190430
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A; Sholzberg M; Buckstein R
Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S
Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.
Park S; Yoon SS; Lee JH; Park JS; Jang JH; Lee JW
Int J Hematol; 2016 Jan; 103(1):44-52. PubMed ID: 26511480
[TBL] [Abstract][Full Text] [Related]
13. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.
Moussa MM; Mowafy N
J Gastroenterol Hepatol; 2013 Feb; 28(2):335-41. PubMed ID: 22849409
[TBL] [Abstract][Full Text] [Related]
14. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
DasGupta RK; Levine L; Wiczer T; Cataland S
J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
16. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Giagounidis A; Kantarjian H; Mufti GJ; Fenaux P; Jia C; Yang AS; Platzbecker U
Br J Haematol; 2014 Nov; 167(3):337-45. PubMed ID: 25039607
[TBL] [Abstract][Full Text] [Related]
18. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
[TBL] [Abstract][Full Text] [Related]
19. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
